Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

被引:44
|
作者
Nakayama, Hirokazu [1 ]
Usuki, Kensuke [2 ]
Echizen, Hirotoshi [3 ]
Ogawa, Ryuichi [3 ]
Orii, Takao [1 ]
机构
[1] NTT Med Ctr Tokyo, Dept Pharm, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan
[2] NTT Med Ctr Tokyo, Dept Hematol, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan
[3] Meiji Pharmaceut Univ, Dept Pharmacotherapy, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan
关键词
eculizumab; dosing interval; breakthrough hemolysis; paroxysmal nocturnal hemoglobinuria; COMPLEMENT INHIBITOR ECULIZUMAB; TERM SAFETY;
D O I
10.1248/bpb.b15-00703
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Eculizumab given bi-weekly is widely recommended for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). We undertook a retrospective analysis on the medical records of 763 dosings of 14 PNH patients to investigate whether a threshold would exist in dosing intervals associated with breakthrough hemolysis. We identified 12 events of breakthrough hemolysis in 4 patients. Multivariate logistic regression and receiver operating characteristics (ROC) analysis revealed a significant association between increased risk of breakthrough hemolysis and prolonged dosing intervals of 17 days or more and concomitant inflammation: odds ratios (OR) and 95% confidence intervals (CIs) were 1.6 (1.3-2.0, p<0.01) and 5.5 (1.3-22.8, p=0.02), respectively. ROC analysis showed that the best cut-off dosing interval discriminating breakthrough hemolysis was 16.5 days. We consider that eculizumab dosing intervals longer than 17 days may be associated with an increased risk for developing breakthrough hemolysis in patients with PNH.
引用
收藏
页码:285 / 288
页数:4
相关论文
共 50 条
  • [41] APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria
    El Mehdil, Delphine
    Grossi, Federico V.
    Deschatelets, Pascal
    Pullon, Humphrey
    Tan, Lisa
    Vega, Carolina A.
    Francois, Cedric G.
    MOLECULAR IMMUNOLOGY, 2017, 89 : 115 - 115
  • [42] Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data
    Kulasekararaj, Austin
    Griffin, Morag
    Piatek, Caroline I.
    Shammo, Jamile
    Nishimura, Jun-Ichi
    Patriquin, Christopher J.
    Schrezenmeier, Hubert
    Gaya, Anna
    Patel, Yogesh
    Liu, Peng
    Filippov, Gleb
    De Fontbrune, Flore Sicre
    Risitano, Antonio M.
    Lee, Jong-Wook
    BLOOD, 2023, 142
  • [43] RAVULIZUMAB VERSUS ECULIZUMAB IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A PROSPECTIVE ANALYSIS ON THE DEEPNESS OF C5 INHIBITION BASED ON PHARMACOKINETICS/PHARMACODYNAMICS AND BREAKTHROUGH HEMOLYSIS OBSERVED IN TWO PHASE 3 RANDOMIZED, MULTICENTER STUDIES
    Risitano, A. M.
    de Latour, R. Peffault
    Rottinghaus, S. T.
    Hillmen, P.
    Ortiz, S.
    Szer, J.
    Schrezenmeier, H.
    Aguzzi, R.
    Hill, A.
    Lee, J. W.
    Kulasekararaj, A. G.
    Brodsky, R. A.
    HAEMATOLOGICA, 2019, 104 : 25 - 25
  • [44] Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients
    Schubert, J.
    Young, N. S.
    Luzzatto, L.
    Brodsky, R. A.
    Socie, G.
    Rother, R. P.
    Rollins, S. A.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis
    Versmold, Katharina
    Alashkar, Ferras
    Raiser, Carina
    Ofori-Asenso, Richard
    Xu, Tao
    Liu, Yutong
    Katz, Pablo
    Shang, Aijing
    Roeth, Alexander
    BLOOD, 2021, 138
  • [46] Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter
    Panse, Jens
    Daguindau, Nicolas
    Sasaki, Sonia Okuyama
    De Latour, Regis Peffault
    Schafhausen, Philippe
    Straetmans, Nicole
    Al-Adhami, Mohammed
    Ajayi, Temitayo
    Chen, Crystal
    Yeh, Michael
    Wong, Raymond S.
    BLOOD, 2021, 138
  • [47] Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry
    Patriquin, Christopher J.
    Kulasekararaj, Austin
    de Latour, Regis Peffault
    Jang, Jun-Ho
    Langemeijer, Saskia
    Maschan, Alexey A.
    Wilson, Amanda
    Jain, Deepak
    Maciejewski, Jaroslaw P.
    BLOOD, 2019, 134
  • [48] A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics
    Weitz, Ilene C.
    Kulagin, Aleksandr
    Nakao, Shinji
    Piatek, Caroline I.
    Szer, Jeffrey
    Rottinghaus, Scott T.
    Volles, Lori
    Damokosh, Andrew I.
    Aguzzi, Rasha
    Larratt, Loree
    Risitano, Antonio M.
    BLOOD, 2018, 132
  • [49] Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU)
    Roth, A.
    Peffault de Latour, R.
    Soret, J.
    Frieri, C.
    Sicre de Fontbrune, F.
    Marano, L.
    Alashkar, F.
    Benajiba, L.
    Marotta, S.
    Kulmatycki, K.
    Nidamarthy, P. K.
    Fagan, N.
    Junge, G.
    Risitano, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 173 - 174
  • [50] LDH=1. 5X ABOVE NORMAL IS A SENSITIVE AND SPECIFIC MARKER TO IDENTIFY PATIENTS AT RISK OF CLINICAL COMPLICATIONS AND MORTALITY ASSOCIATED WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Lee, J.
    Jang, J. H.
    Kim, J. S.
    Yoon, S. S.
    Lee, J. H.
    Kim, Y. K.
    Jo, D. Y.
    Chung, J.
    Sohn, S. K.
    HAEMATOLOGICA, 2012, 97 : 579 - 580